Our Company
Culture & Values
Leadership
Global Locations
Corporate Compliance
Subsidiaries & Joint Ventures
Diversity & Inclusion
20th Anniversary
Medicinal Chemistry
Compound Screening
DMPK
Safety & Toxicology
Bioanalytical
CMC
Medical Writing
Clinical Monitoring
Regulatory Affairs
Data Management and Statistical Analysis
Clinical Development Strategy
Decentralized Clinical Trials (DCTs)
Site Management (SMO)
Medical Device / IVD
Multi-region Clinical Trial (MRCT)
Vaccine Clinical Trial
Tigermed Insight
Your Full-Service CRO of Choice for Global Clinical Development
Jul 03, 2025
|
We are proud to share with you our latest updates on Tigermed global capabilities and layout for your clinical development. As a global CRO partner with 10,000+ employees worldwide, we are committed to helping you deliver life-changing therapies with speed and efficiency. With over 20 years of legacy and a strong proven track record, our integrated solutions are able to drive your drug and medical device development and approvals in North America, EMEA, China, Australia, Japan, South Korea, Southeast Asia and Latin America. Here are the resources and expertise you can have while partnering with us.
Tigermed in North America Our US and Canada teams provide efficient, high quality clinical development solutions for the rapid commercialization of your products. • 200+ employees in US & Canada. PMs and CRAs spread across 27 States and 68 cities in the US. • Over 110 clinical studies in 20+ therapeutic areas since 2019 • Top-tier network with 700+ sites across 45+ States
Tigermed in EMEA (Europe, Middle East, and Africa) We operate in 20+ EMEA countries, offering tailored and full-service solutions for pharmaceuticals and medical devices. • 15 offices with 160+ employees across Western to Eastern Europe • 200+ phase I-IV trials conducted by European team • 30+ years of experience in regulatory, drug safety, and clinical operations, etc.
Tigermed in China We are the leading clinical CRO with the largest clinical outsourcing market share in China, according to Frost & Sullivan report. • End-to-End R&D services from preclinical to clinical to post-market • Over 1,500 clinical sites engaged • 150+ offices and service networks • Supported 60% of China NMPA-approved innovative drugs since 2004
Tigermed in Australia Supporting your Australian early-phase studies with extensive therapeutic experience and global project management. • 40+ local PM/PD/CRA/CTA with decades of experiences • Collaborating with 20+ major Oncology sites in Australia • 70+ phase I clinical studies in Australia with 15+ indications • Solid relationships with local Oncology KOLs
Tigermed in Japan Delivering your studies with expertise from our Japanese subsidiaries: Tigerise and Medical Edge. • 110+ local CRAs, 60% of which with 7-10 years of experience • Offices in Tokyo and Osaka, CRC services spread out 300+ hospitals and sites in Japan • Local capabilities in clinical operation, data management, EDC, and pharmacovigilance, etc.
Tigermed in South Korea Our Korean subsidiary--DreamCIS, one of the largest and the first clinical CRO listed in Korea Stock Exchange (KRX). • 450+ employees in South Korea with 2,600+ clinical studies • Full services from regulatory and consulting, to clinical development and market access • Highly disciplined execution for MRCT and single-region trial
Tigermed in Southeast Asia and Latin America Strategically located in nearly 20 countries & regions and providing custom-built delivery solutions. • 100+ Phase I-IV studies in Southeast Asia with 70+ employees • Biometrics team of experts in India • Experienced in large-scale clinical studies in Latin America, including COVID-19 vaccine trials |
